Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

demonstrated encouraging potential in initial clinical studies," said David Tabagari, M.D., Ph.D., the head of Medulla Immunotherapy and Chemotherapy Clinic and principal investigator of the bavituximab breast cancer trial being conducted in the Republic of Georgia. "We are pleased to have the opportunity to conduct the first Phase II trial of this potentially valuable new approach to treating cancer."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has recently received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol testing
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 26, 2014 "Ischemic Stroke and ... provides data on the Ischemic Stroke and Cerebral ... information and data relating to the clinical trials ... full global Ischemic Stroke Research Report 2014 at: ... of the trial numbers and their recruitment status ...
(Date:7/25/2014)... from the University of Leicester has furthered our ... potential to create new materials using nanosized ,building ... in the prestigious academic journal Physical Review ... examine in rich detail the structure and internal ... acetylene molecule and a single helium atom. , ...
(Date:7/25/2014)... San Diego, CA (PRWEB) July 25, 2014 ... “Paws” For Your Pet with Lorry Young will be ... DVM, to talk about stem cell therapy in pets. ... discuss the benefits of stem cell therapy for pets suffering ... developments moving the Regenerative Veterinary Medicine industry forward. , Young ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... new kind of biosensor can tell., A new and ... Vanderbilt University that can measure the interactions between free-floating, ... RNA., That is precisely the kind of capability needed ... have been opened up by the 15-year-plus effort to ...
... have developed tools to help solve two of the main ... to quickly test stem cell response to different drugs or ... viable stem cells to study from only a few available ... of stems cells on devices the size of a standard ...
... approach to discover life on Mars were successfully launched ... orbit experiment to assess their survivability in the space ... new approach is based on technology similar to that ... embodied in the Life Marker Chip (LMC) experiment, which ...
Cached Biology Technology:When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell 2When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell 3Putting stem cell research on the fast track 2Putting stem cell research on the fast track 3Putting stem cell research on the fast track 4Life on Mars 'pregnancy test' successfully launched 2
(Date:7/28/2014)... CITY (July 28, 2014)The Brain & Behavior Research ... Klerman and Freedman Prizes, recognizing exceptional clinical and ... supported by NARSAD Young Investigator Grants. The grants ... in neurobiological and psychosocial research for the prevention, ... that affect one in four people. , Six ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
(Date:7/28/2014)... statistical tools to map social connections in prairie ... techniques, shedding light on prairie dog communities that ... and guide future conservation efforts. The work was ... and the National Evolutionary Synthesis Center (NESCent). , ... to bubonic plague," says Dr. Jennifer Verdolin, lead ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Interfering with interferon 2Social network research may boost prairie dog conservation efforts 2
... Ill. --- Driving down a country road at night your ... creature doesnt move. Depending on your speed and other conditions, ... you do, its because you are in what is fittingly ... study, published online Nov. 13 by the journal PLoS Biology. ...
... CAMBRIDGE, MA MIT researchers have identified a family of ... critical for normal brain function. Their research could lead ... The team, led by MIT biology professor Frank Gertler, ... to direct the formation of axons and dendrites, the ...
... professor of biology in Arts & Sciences, has been awarded ... study pathways in bioenergy conversion. One is a long-term NIH ... $1,203,250. It started on August 1. The renewal award means ... The U.S. Department of Agriculture, U.S. Department of Energy, ...
Cached Biology News:Northwestern study looks at sensing, movement and behavior 2Northwestern study looks at sensing, movement and behavior 3MIT IDs proteins key to brain function 2NIH grants enable energy studies 2NIH grants enable energy studies 3
... 13(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 13(S)-HODE is produced by incubation of linoleic acid ... shown to inhibit the adhesion of tumor cells ...
... 4700 Proteomics Analyzer Mass Standards Kit includes ... instrument function, optimize instrument parameters, and calibrate ... This kit is designed for use with ... mass spectrometry system. Standards in the kit ...
...
...
Biology Products: